• SARS-CoV-2

    ELISA test systems from EUROIMMUN

Anti-SARS-CoV-2 ELISA IgG / Anti-SARS-CoV-2 QuantiVac ELISA (IgG)

  • Specific detection of IgG antibodies against SARS-CoV-2 using the S1 domain of the spike protein including the immunologically relevant receptor binding domain (RBD)
  • RBD represents important target antigen for virus neutralising antibodies
  • Worldwide programs for vaccine development use the spike protein as antigen
  • Available as ELISA for semi-quantitative and quantitative determination (same cut-off-calibrator)
  • Excellent performance and good correlation with neutralisation tests confirmed by external studies (Anti-SARS-CoV-2 ELISA)
  • Validated for serum, plasma and dried capillary blood as sample material, complete automation possible

Customer comments and testimonials about SARS-CoV-2 ELISA (IgG)

 

ProductIg classFormatIncluded controlsOrder no.Status
Anti-SARS-CoV-2 ELISA IgG96 x 01
96 x 20		pos. control, neg. controlEI 2606-9601 G
EI 2606-9620 G*		CE-marked
FDA EUA
Anti-SARS-CoV-2 QuantiVac ELISA (IgG)IgG96 x 01EI 2606-9601-10 GCE-marked

*Optimized for processing with the EUROLabWorkstation ELISA

Anti-SARS-CoV-2 NCP ELISA (IgG) or (IgM)

  • Sensitive detection of IgG or IgM antibodies against SARS-CoV-2 using the nucleocapsid protein
  • Antigen with the strongest immune dominance in the coronavirus family
  • Optimised specificity of the ELISA due to the use of a modified nucleocapsid protein (NCP) that only contains diagnostically relevant epitopes
  • Validated for serum, plasma and dried capillary blood (DBS only in combination with the IgG ELISA) as sample material, complete automation possible

   

ProductIg classFormatIncluded controlsOrder no.Status
ELISA IgG96 x 01
96 x 20		pos. control, neg. controlEI 2606-9601-2 G
EI 2606-9620-2 G*		CE-marked
ELISAIgM96 x 01EI 2606-9601-2 M**

*Optimized for processing with the EUROLabWorkstation ELISA
** Optimized for processing with EUROIMMUN Analyzer I / I-2P and Sprinter XL

Anti-SARS-CoV-2 ELISA IgA

  • Sensitive ELISA for the determination of IgA against SARS-CoV-2 with optimised specificity due to use of the Sample Buffer PLUS
  • Use of the S1 domain of the spike protein as the antigen
  • For monitoring of the immune response after positive direct pathogen detection

   

ProductIg classFormatIncluded controlsOrder no.Status
ELISAIgA96 x 01
96 x 20		pos. control, neg. controlEI 2606-9601 A
EI 2606-9620 A		CE-marked

In a nutshell: Product features of the EUROIMMUN ELISAs for COVID-19 diagnostics

Product featureAnti-SARS-CoV-2 ELISA (IgG)Anti-SARS-CoV-2-QuantiVac-ELISA (IgG)Anti-SARS-CoV-2 ELISA (IgA) Anti-SARS-CoV-2 NCP ELISA (IgG)Anti-SARS-CoV-2 NCP ELISA (IgM)
AntigenS1 domaine of the spike proteinModified nucleocapsid protein (NCP)
Sample materialSerum, plasma, DBSSerum, plasma, DBSSerum, plasma, DBSSerum, plasma, DBSSerum, plasma, DBS
Sensitivity94,4 %
(>10 days**)		90,3 %
(>10 days**)		96,9 %
(11 - 60 days**)		94,6 %
(>10 days**)		88,2 %
(<10 days**)
Specificity99,6 %99,8 %98,3 %99,88 %98,6 %
Complete automation of DBS analysesPossiblePossible-Possible-
ELISA automationEUROLabWorkstation ELISA (ELW ELISA), EUROIMMUN Analyzer I, EUROIMMUN Analyzer I-2P, Sprinter XL
Stability of test kits12 months6 months

**after symptom onset or positive direct detection

Options for automated processing of the EUROIMMUN ELISA

1. EUROIMMUN Automation Solutions:

EUROLabWorkstation ELISA, Analyzer I, Analyzer I-2P and Sprinter XL

For further information on our automation options, please contact our experts of product management for instruments and software.

2. Processing on all common open ELISA platforms